Key result
Intravenous cangrelor produced greater P2Y12 inhibition at the time of initial coronary balloon inflation compared to oral ticagrelor in STEMI patients.
Why the study?
Oral P2Y12 inhibitors have delayed antiplatelet action in acute myocardial infarction, whereas intravenous P2Y12 inhibition might provide more timely and potent inhibition during primary angioplasty, potentially improving myocardial recovery.
Does intravenous cangrelor provide superior platelet inhibition, microvascular function, and infarct size reduction compared to oral ticagrelor in patients with STEMI undergoing primary PCI?
RCT (n=100)
Open-label
1:1
Does intravenous cangrelor provide superior platelet inhibition, microvascular function, and infarct size reduction compared to oral ticagrelor in patients with STEMI undergoing primary PCI?
Intravenous cangrelor provides more potent and rapid platelet inhibition at the time of primary PCI for STEMI compared to oral ticagrelor, but this enhanced pharmacodynamic effect does not translate to improved microvascular function or reduced infarct size.
Answers are grounded in this paper and cite their sources.
Cangrelor yields faster P2Y12 inhibition than ticagrelor during STEMI PCI; no microvascular or infarct-size benefit observed, challenging presumed clinical translation.
BACKGROUND: Oral P2Y12 inhibitors take more than 2 hours to achieve full effect in healthy subjects and this action is further delayed in patients with acute myocardial infarction. Intravenous P2Y12 inhibition might lead to more timely and potent anti-platelet effect in the context of emergency primary angioplasty, improving myocardial recovery. OBJECTIVES: This article compares the efficacy of intravenous cangrelor versus ticagrelor in a ST-elevation myocardial infarction (STEMI) population treated with primary percutaneous coronary intervention (PPCI). MATERIALS AND METHODS: In an open-label, prospective, randomized controlled trial, 100 subjects with STEMI were assigned 1:1 to intravenous cangrelor or oral ticagrelor. The co-primary endpoints were platelet P2Y12 inhibition at infarct vessel balloon inflation time, 4 and 24 hours. Secondary endpoints included indices of coronary microcirculatory function: index of microvascular resistance (IMR), initial infarct size (troponin at 24 hours) and final infarct size at 12 weeks (cardiac magnetic resonance). Secondary endpoints included indices of coronary microcirculatory function (index of microvascular resistance [IMR]), initial infarct size (troponin at 24 hours), final infarct size at 12 weeks (cardiac magnetic resonance), corrected thrombolysis in myocardial infarction (TIMI) frame count, TIMI flow grade, myocardial perfusion grade, and ST-segment resolution (ClinicalTrials.gov NCT02733341). RESULTS: P2Y12 inhibition at first balloon inflation time was significantly greater in cangrelor-treated patients (cangrelor P2Y12 reaction unit [PRU] 145.2 ± 50.6 vs. ticagrelor 248.3 ± 55.1). There was no difference in mean PRU at 4 and 24 to 36 hours post-dosing. IMR, final infarct size, angiographic and electrocardiographic measures of reperfusion were all similar between groups. CONCLUSION: Cangrelor produces more potent P2Y12 inhibition at the time of first coronary balloon inflation time compared with ticagrelor. Despite this enhanced P2Y12 inhibition, coronary microvascular function and final infarct size did not differ between groups.
No takes yet. Share an insight, caveat, or question.
Ubaid et al. (2019) conducted an RCT in ST-segment elevation myocardial infarction (STEMI) (n=100). Cangrelor vs. Ticagrelor was evaluated on P2Y12 inhibition at the time of first intracoronary balloon inflation (measured in P2Y12 reaction units [PRU]) (p=<0.001). Intravenous cangrelor produced greater P2Y12 inhibition at the time of initial coronary balloon inflation compared to oral ticagrelor in STEMI patients.
Synapse has enriched 10 related papers. Consider them for comparative context: